Why Should You Put Akebia Therapeutics Inc. (NASDAQ: AKBA) On Your Portfolio?

Currently, there are 194.58M common shares owned by the public and among those 184.15M shares have been available to trade. The company’s stock has a 5-day price change of 31.25% and 67.26% over the past three months. AKBA shares are trading 52.42% year to date (YTD), with the 12-month market performance up to 165.23% higher. […]

Akebia Therapeutics Inc. (NASDAQ: AKBA): The Best-Of-Breed For Investing?

Currently, there are 184.14M common shares owned by the public and among those 165.56M shares have been available to trade. Insiders at the company have transacted a total of 30 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, […]

There Is Clear Momentum For Akebia Therapeutics Inc. (NASDAQ: AKBA)

Millennium Management LLC has recently announced that it has increased stake in Akebia Therapeutics Inc. (NASDAQ:AKBA) by 52.18%. After grabbing 3.05 million shares, the institutional investor is now in possession of 1.05 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.62% having worth around $3.24 million. Moreover, […]

Technical Outlook And Game Plan For Akebia Therapeutics Inc. (NASDAQ: AKBA)

Akebia Therapeutics Inc. (AKBA) concluded trading on 12/28/23 at a closing price of $1.28, with 3.83 million shares of worth about $4.9 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.32% during that period and on Thursday the price saw a gain of […]